Novartis Everolimus Oral Dosing May Offer Advantages Over Wyeth's Torisel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis halts Phase III study of the mTOR inhibitor early after everolimus shows better progression-free survival than placebo.